Literature DB >> 31935714

Management of the Elderly Inflammatory Bowel Disease Patient.

Petr Hruz1, Pascal Juillerat2, Gerd-Achim Kullak-Ublick3, Alain M Schoepfer4, Gerassimos J Mantzaris5, Gerhard Rogler6.   

Abstract

Inflammatory bowel disease (IBD) is increasingly diagnosed among elderly persons (older than 60 years). Epidemiological studies show that late-onset IBD is characterized by predominance of colonic disease, milder disease course, and less frequent occurrence of extraintestinal manifestations. However, due to comorbidities, polypharmacy and reduced resistance to severe disease course elderly patients have an increased risk of mortality. Drug treatment generally follows the same algorithms as in the younger IBD patients. This is challenging for the treating physician as this population is usually underrepresented in clinical trials and treatment outcomes as well as safety data on the elderly population are scarce. Choice of drugs should consider risk of infections, skin cancer, lymphoma, and metabolic as well as cardiovascular side effects. Considering comorbidities, surgical interventions such as colectomy with ileo-anal pouch anastomosis for refractory ulcerative colitis can be performed safely provided that the anal sphincter function is adequately maintained. Special attention should be given in this age group to general health issues, including nutrition, vaccination, bone, muscle, and mental health as well as colorectal and skin cancer screening.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Crohn’s disease; Elderly; Management; Ulcerative colitis

Year:  2020        PMID: 31935714     DOI: 10.1159/000503099

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  Green tea EGCG effectively alleviates experimental colitis in middle-aged male mice by attenuating multiple aspects of oxi-inflammatory stress and cell cycle deregulation.

Authors:  Bhawna Diwan; Rohit Sharma
Journal:  Biogerontology       Date:  2022-07-02       Impact factor: 4.277

Review 2.  Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?

Authors:  Pascal Juillerat; Maude Martinho Grueber; Roseline Ruetsch; Giulia Santi; Marianne Vuillèmoz; Pierre Michetti
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-04-28

Review 3.  Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

Authors:  Gustavo Drügg Hahn; Petra Anna Golovics; Panu Wetwittayakhlang; Dirlene Melo Santa Maria; Usiara Britto; Gary Edward Wild; Waqqas Afif; Alain Bitton; Talat Bessissow; Peter Laszlo Lakatos
Journal:  J Clin Med       Date:  2022-07-29       Impact factor: 4.964

4.  Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.

Authors:  Gustavo Drügg Hahn; Jean-Frédéric LeBlanc; Petra Anna Golovics; Panu Wetwittayakhlang; Abdulrahman Qatomah; Anna Wang; Levon Boodaghians; Jeremy Liu Chen Kiow; Maryam Al Ali; Gary Wild; Waqqas Afif; Alain Bitton; Peter Laszlo Lakatos; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2022-09-07       Impact factor: 5.374

5.  Increased Risk of Inflammatory Bowel Disease Among Patients With Ankylosing Spondylitis: A 13-Year Population-Based Cohort Study.

Authors:  Shuya Wang; Hsi-Kai Tsou; Jeng-Yuan Chiou; Yu-Hsun Wang; Zhiyi Zhang; James Cheng-Chung Wei
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.